Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trial

Transarterial chemoembolization (TACE) is the standard-of-care for unresectable intermediate-stage HCC[1]. Although TACE has been widely used for several years, the procedure varies widely across centres and interventional radiologists, especially regarding chemotherapeutic agents, doses, drug-releasing vectors, and embolization agents[2]. This heterogeneity is explained by the absence of proof to clarify the mechanism by which TACE improves patient survival. Some clinicians believe that embolization plays a major role and that adding a chemotherapeutic agent does not improve efficacy.

Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: Boris Guiu, Jean-Louis Jouve, Antonin Schmitt, Anne Minello, Franck Bonnetain, Christophe Cassinotto, Lauranne Piron, Jean-Pierre Cercueil, Romaric Loffroy, Marianne Latournerie, Ma ëva Wendremaire, Côme Lepage, Mathieu Boulin Source Type: research